Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
NASDAQ:NKTR
Price:
1.32 USD
Market Closed
Updated:
Apr 29, 2024
Nektar Therapeutics
Cash from Financing Activities
|
Nektar Therapeutics
Cash from Financing Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Cash from Financing Activities
$30k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-87%
|
CAGR 10-Years
-35%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$15.8B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
-$9.4B
|
CAGR 3-Years
-101%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-24%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$4.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
18%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$3.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Nektar Therapeutics's Cash from Financing Activities?
Cash from Financing Activities
30k
USD
30k
USD
Based on the financial report for Dec 31, 2023, Nektar Therapeutics's Cash from Financing Activities amounts to 30k USD.
What is Nektar Therapeutics's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-35%
-35%
Over the last year, the Cash from Financing Activities growth was -98%.
You don't have any saved screeners yet
